{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:34:45Z","timestamp":1790854485453,"version":"4.1.0"},"reference-count":14,"publisher":"Wiley","issue":"15","license":[{"start":{"date-parts":[[2009,10,20]],"date-time":"2009-10-20T00:00:00Z","timestamp":1255996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2009,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pilot study of nabilone in Huntington's disease (HD). Double\u2010blind, placebo\u2010controlled, cross\u2010over study of nabilone versus placebo. Primary outcome, Unified Huntington's Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = 22), or placebo followed by nabilone (n = 22). Recruiting was straightforward. Nabilone safe and well tolerated, no psychotic episodes. Assessment of either dose of nabilone versus placebo showed a treatment difference of 0.86 (95% CI: \u22121.8 to 3.52) for total motor score; 1.68 (95% CI: 0.44 to 2.92) for chorea; 3.57 (95% CI: \u22123.41 to 10.55) for UHDRS cognition; 4.01 (95% CI: \u22120.11 to 8.13) for UHDRS behavior, and 6.43 (95% CI: 0.2 to 12.66) for the NPI. Larger longer RCT of nabilone in HD is feasible and warranted. \u00a9 2009 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.22809","type":"journal-article","created":{"date-parts":[[2009,10,20]],"date-time":"2009-10-20T16:33:22Z","timestamp":1256056402000},"page":"2254-2259","source":"Crossref","is-referenced-by-count":123,"title":["A pilot study using nabilone for symptomatic treatment in Huntington's disease"],"prefix":"10.1002","volume":"24","author":[{"given":"Adrienne","family":"Curtis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smitaa","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Ives","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Rickards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,10,20]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.71.3.310"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.8.2.141"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704327"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61162-3"},{"key":"e_1_2_6_6_2","first-page":"s115","article-title":"The cannabinoids in MS study\u2010final results from 12 month follow up","volume":"10","author":"Zajicek J","year":"2004","journal-title":"Multiple Sclerosis"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.3.7.899"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200317030-00004"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.2006.18.4.553"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(199911)14:6<1038::AID-MDS1024>3.0.CO;2-7"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110204"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.12.2308"},{"key":"e_1_2_6_13_2","volume-title":"Design and analysis of cross\u2010over trial","author":"Jones B","year":"1998"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/0470854596"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2005.070136"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.22809","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.22809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:44:51Z","timestamp":1760964291000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.22809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,20]]},"references-count":14,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2009,11,15]]}},"alternative-id":["10.1002\/mds.22809"],"URL":"https:\/\/doi.org\/10.1002\/mds.22809","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,20]]}}}